Affiliation:
1. Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt
Abstract
Doxorubicin is one of the most effective anthracycline anticancer drugs, but it causes several adverse effects. Our study was designed to assess the consequences of combining doxorubicin with chloroquine or gemifloxacin. Drugs cytotoxicity was assessed on two different cell lines; A549 lung adenocarcinoma and MCF7 breast cancer. The in-vitro oxidative stress was also measured. In the in-vivo experiment, Ehrlich ascetis carcinoma-bearing mice, different treatments with doxorubicin, chloroquine, gemifloxacin and their combinations were evaluated. Survival indices (MST and ILS%) and blood biochemical parameters as well as the histopathological picture were studied. Results showed that, doxorubicin combinations were more cytotoxic on MCF7 and A549 cell lines than doxorubicin alone. The combinations significantly decreased the oxidative stress resulted from doxorubicin treatment. Furthermore, these combinations improved hematological parameters and histopathological pictures in the treated mice. In conclusion, chloroquine and gemifloxacin significantly enhance the antitumor properties of doxorubicin and reduce its toxicity.
Publisher
Oriental Scientific Publishing Company
Reference26 articles.
1. Halazonetis, T.D., V.G. Gorgoulis, and J. Bartek. 2008.An oncogene-induced DNA damage model for cancer development. Science,319,1352-5.
2. Alapati, V., et al. 2012.In vivo anti-tumour activity of novel Quinazoline derivatives. European Review for Medical and Pharmacological Sciences,16,1753-64.
3. Taatjes, D.J., et al. 1998.A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer. Current pharmaceutical design,4,203-218.
4. Drlica, K. and X. Zhao. 1997.DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews,61,377-92.
5. Coughlin, S.A., et al. 1995.Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161). Biochemical Pharmacology,50,111-22.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献